Where longevity escapes velocity – Founders Longevity Forum explored breakthrough therapies, age reversal and paths to scalable rejuvenation.
From Bryan Johnson’s call to treat health as humanity’s core product to in-depth discussions on founder biology, biotech innovation and systemic rejuvenation, the subsequent Founders Longevity Forum sessions advanced into Longevity 2.0 and 3.0 within Phil Newman’s Ten Levels of Longevity model. This strategic recap spotlights emerging therapies, biological age reversal and the frontier of digital or corporeal preservation – key steps as the field moves from experimentation to scalable, validated interventions. While not every speaker or session is detailed, this overview captures the major themes shaping the next wave of human health innovation.
From managing age-related disease to exploring cellular reprogramming and cryopreservation, this second half of the Forum highlighted both the immense promise and complexity of what comes next.
Longevity 2.0: Clinics, services and decelerating aging
The focus of Longevity 2.0 was clear: moving from optimising healthspan to modifying disease, reversing biological age and expanding lifespan through data-driven care and emerging therapeutics.
Founders’ biology
Stephen Watson (Founders Health) made a compelling case for treating biological data as a business KPI. Startup leaders age 2.3x faster than average, and burnout precedes nearly 60% of company shutdowns. Yet while VCs scrutinize tech and market fit, biological due diligence is rarely done. Health and performance, Watson argued, are inseparable – 79% of successful exits came from founders who tracked their biology like they tracked revenue. It doesn’t have to be a choice between time and money, longevity and business success can coexist. The question is, who’s brave enough to do both?
Clinical infrastructure
Dr William Kapp (Co-Founder & Chief Executive Officer, Fountain Life) outlined a next-generation clinical model, co-founded with Peter Diamandis and Tony Robbins, integrating multi-omic diagnostics, AI and human coaching to shift healthcare from reactive to preventive. With 7 in 10 deaths in the US deemed preventable, Kapp emphasised the need to train clinicians not just in pathology, but in longevity optimisation.
Building on this, Faye Mythen (Consulting CEO, Reborne Longevity Ltd) described a vision where luxury hospitality, medical-grade compliance and consumer-level data fluency converge. In her words, “longevity must meet medical wellness and hospitality,” and success lies not just in the science, but in trust, design and experience. Community, scientific credibility and human connection are now critical differentiators in this fast-evolving sector.
Moderator Joanna Bensz (Founder & CEO, Longevity Centre Europe) noted that while longevity clinics are pioneering a new medical frontier, shared standards and clinical protocols are still lacking. With no formal training pathway in longevity medicine, most practitioners rely on a mix of integrative, functional and self-taught approaches, a gap the industry must urgently address.
Targeting aging at its roots
Shifting into Longevity 2.0 therapeutics, Reason (Repair Biotechnologies) introduced a novel intervention targeting toxic intracellular cholesterol, a key contributor to atherosclerosis. His team’s lipid nanoparticle-mRNA therapy enables localised degradation of cholesterol inside cells, potentially reversing plaque and restoring vascular function, a major step toward tackling age-related disease at its core.
In the following panel, Alexandra Bause (Co-Founder & Venture Partner, Apollo Health Ventures), Eric Morgen (Co-Founder & COO, BioAge), and Reason, moderated by Todd White (Managing Director, The Thalion Initiative), explored how AI and big data are flipping traditional research models. Rather than relying solely on preclinical animal studies, teams are training models on vast real-world datasets to drive insight and therapeutic innovation.
The discussion closed with speculative but grounded ideas for high-impact interventions:
- Rapalog (rapamycin analogue) therapeutics targeting mTOR, a key nutrient-sensing pathway whose inhibition has been shown to extend lifespan in multiple species.
- Pathobiont or flagellin immunisation to modulate the microbiome and prevent dysbiosis.
- Sarcopenia-prevention agents to preserve muscle in synergy with GLP-1s, enhancing mitochondrial function, energy and vitality.
Longevity 3.0: Age reversal, systemic rejuvenation and longevity investment
Longevity 3.0 sessions explored the most forward-leaning ideas, cellular reprogramming, systemic rejuvenation and cryopreservation, pointing to a future where aging might not just be slowed, but reversed.
Epigenetic reprogramming and cellular reset
Stasa Stankovic (Co-founder & CEO, OvartiX) chaired a panel on targeted age reversal, drawing from her own work on ovarian aging as a proxy for biological age. Daniel Ives (CEO & Founder, Shift Bioscience) presented preclinical findings on SB000, a novel single-gene target that may mimic the rejuvenating effects of Yamanaka factors (OSKM) without inducing pluripotency, suggesting a safer path toward cellular age reversal across multiple cell types.
Sharon Rosenzweig-Lipson (Chief Scientific Officer, Life Biosciences) shared encouraging data on partial epigenetic reprogramming using OSK, demonstrating restored visual function in non-human primates, one of the first real-world applications of reprogramming beyond the petri dish.
Systemic aging and multi-organ rejuvenation
In a session moderated by Dame Molly Stevens (Professor of Biomedical Materials and Regenerative Medicine, Imperial College London), Patrick Burgermeister (General Partner, RegenEra Ventures) argued that aging is inherently systemic – no organ declines in isolation. Interventions targeting one hallmark of aging often trigger cascading benefits. Yet while pharma continues to focus on narrow molecular targets, companies aiming at root-cause pathways may unlock broader therapeutic synergies and unforeseen positive side effects.
Longevity investment: Biotech, biostasis and capital constraints
The final panel, moderated by Phil Newman (Founder & CEO, Longevity.Technology), featured Laura Deming (CEO, Cradle, Co-Founder & Venture Partner, age1, Founder, Longevity Fund), Will Harborne (Founding Partner & GP, LongGame Ventures) and Yehudah Nevies (Director Investor Relations, Juvenescence, discussing the rapidly shifting biotech investment landscape.
Deming highlighted the potential of cryopreservation (biostasis), noting it already underpins IVF. The real question: can we scale it safely and ethically for broader use cases, such as preserving cancer patients who won’t live long enough to benefit from next-generation therapies?
The Middle East was also cited as an emerging hub for building preventative longevity infrastructure from the ground up.
The panel’s consensus? The science is outpacing capital. Longevity has few exits, long clinical timelines and limited validated endpoints, but GLP-1 agonists offer a roadmap, showing how rapid adoption is possible when a therapy combines strong efficacy with broad demand.
Closing reflections
The Founders Longevity Forum London made one thing clear: science is moving fast, but investment, regulation and clinical readiness are lagging behind. Whether through cellular reprogramming, multi-omic diagnostics or cryopreservation, the goal remains the same: extend life, preserve function, and do so ethically and accessibly.
By framing the event around Longevity 1.0, 2.0 and 3.0, Founders Longevity Forum has not only mapped the state of the field, but also raised deeper questions: how far are we willing to go, and what will it take to get there?
Stay tuned for future editions in San Francisco and Singapore coming soon!
The post FLF:LN – From founder biology to future biotech appeared first on Longevity.Technology – Latest News, Opinions, Analysis and Research.
